TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal

被引：26

作者：

Govindan, Ramaswamy ^{[1
,2
]}

Weber, Jason ^{[1
,2
]}

机构：

[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[2] Washington Univ, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA

来源：

CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 17期

关键词：

P53; MUTATIONS; MUTANT P53; SURVIVAL; CARCINOMA; RAS;

D O I：

10.1158/1078-0432.CCR-14-0899

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in TP53 are common in non-small cell lung cancer. Apart from the loss of tumor-suppressor functions, TP53 mutations may result in gain of function favoring cellular proliferation, inhibition of apoptosis, and genomic instability. Some TP53 mutations are more likely to affect the course of the disease than others. (C) 2014 AACR.

引用

页码：4419 / 4421

页数：3

共 50 条

[31] TP53 mutations in myelodysplastic syndrome
Misawa, S
Horiike, S
LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 417 - 422
[32] Landscape of TP53 Mutations in MPN
Farnoud, Noushin
Famulare, Christopher
Papaemmanuil, Elli
McGovern, Erin
Medina, Juan
Ossa, Juan E. Arango
Rampal, Raajit K.
Li, Bing
Levine, Ross L.
Mascarenhas, John
Weinberg, Rona Singer
Patel, Minal A.
Hoffman, Ronald
BLOOD, 2019, 134
[33] Germline mutations in the TP53 gene
Eeles, RA
CANCER SURVEYS, 1995, 25 : 101 - 124
[34] TP53 mutations in human meningiomas
Verheijen, FM
Sprong, M
Kloosterman, JME
Blaauw, G
Thijssen, JHH
Blankenstein, MA
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (01): : 42 - 48
[35] TP53 mutations sensitize to decitabine
Peter Sidaway
Nature Reviews Clinical Oncology, 2017, 14 : 72 - 72
[36] Not all CALR mutations are created equal
He, Rong
Hanson, Curtis A.
Chen, Dong
Oliveira, Jennifer L.
Pardanani, Animesh
Reichard, Kaaren K.
Viswanatha, David S.
LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2482 - 2483
[37] Are all KRAS mutations created equal?
Stinchcombe, Thomas E.
Der, Channing J.
LANCET ONCOLOGY, 2011, 12 (08): : 717 - 718
[38] KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients
Gao, Weimin
Jin, Jide
Yin, Jinling
Land, Stephanie
Gaither-Davis, Autumn
Christie, Neil
Luketich, James D.
Siegfried, Jill M.
Keohavong, Phouthone
MOLECULAR CARCINOGENESIS, 2017, 56 (02) : 381 - 388
[39] The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.
Ma, Xiaolong
Zhang, Ding
Chen, Shiqing
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40] TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
Lee, Eung Bae
Jin, Guang
Lee, Shin Yup
Park, Ji Young
Kim, Min Jung
Choi, Jin Eun
Jeon, Hyo Sung
Cha, Seung Ick
Cho, Sukki
Kim, Chang Ho
Park, Tae-In
Jung, Tae Hoon
Son, Ji-Woong
Park, Jae Yong
JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 698 - 705

← 1 2 3 4 5 →